Semaglutide and Cardiovascular Benefits

Cardiovascular Benefits of Semaglutide

Semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with type 2 diabetes 1, 2, 3
The SUSTAIN-6 trial demonstrated that semaglutide reduced the primary cardiovascular outcome by 26% compared to placebo (HR 0.74 [95% CI 0.58–0.95]; P < 0.001) 2, 4
The American College of Cardiology recommends semaglutide for patients with established cardiovascular disease and type 2 diabetes, as it provides significant cardiovascular benefits beyond glycemic control and weight loss 1, 2, 4

Semaglutide appears to provide cardiac benefits through multiple mechanisms, including reduced myocardial work and filling pressures, pre- and afterload reduction, improved cardiovascular risk profile and lower blood pressure, reduced atherogenesis, and upregulated nitric oxide and suppressed NF-κB activation 5

Common adverse events with semaglutide are primarily gastrointestinal 2, 4
The American College of Cardiology suggests using semaglutide with caution in patients with a history of pancreatitis, severe renal impairment, or prior gastric surgery 5

In the STEP-1 trial, semaglutide resulted in a mean weight reduction of 12.4% and a 5.1 mmHg reduction in systolic blood pressure in patients with type 2 diabetes 6

Semaglutide can be considered as part of a comprehensive approach to managing cardiovascular risk in patients with hypertension, especially when comorbid with obesity or diabetes, according to the European Heart Journal and the Journal of the American College of Cardiology 6, 7

When initiating semaglutide for patients with hypertension, start with gradual dose titration to minimize gastrointestinal side effects, beginning with 0.25 mg weekly for 4 weeks, then increase to 0.5 mg, 1.0 mg, and 1.7 mg weekly every 4 weeks until reaching the maintenance dose of 2.4 mg after 16 weeks, as recommended by Gastroenterology 8
Monitor blood pressure regularly during titration and maintenance phases, and be aware of common adverse effects, primarily gastrointestinal, including nausea and vomiting, which are usually transient, as noted by the Journal of the American College of Cardiology 7